Moffitt Cancer Center
For patients who have been diagnosed with multiple myeloma or suspect they may have the condition, Moffitt Cancer Center’s Malignant Hematology Program offers some of the best cancer treatment options available and can provide these services all at one convenient location. Our multiple myeloma program is comprised of physicians who each specialize in a different aspect of cancer evaluation, treatment and supportive care. Some of the members of our multiple myeloma team include: Medical oncologists, Radiation oncologists, Orthopedic specialists, Radiologists, Bone marrow transplant specialists, Experienced nurses, and supportive care providers. Together, these specialists meet in a weekly tumor board to discuss each case and formulate effective treatment plans based on each patient’s condition. These plans may include chemotherapy, radiation therapy, bone marrow transplants, clinical trials or any combination thereof, in addition to a supportive care plan to help the patient manage any symptoms or side effects. Thanks to this holistic approach to treating multiple myeloma, as well as our dedication to developing new, groundbreaking clinical trials, Moffitt has been recognized as a Comprehensive Cancer Center by the National Cancer Institute.
This study will test the safety and activity of SGN-CD48A given every 3 weeks to patients with multiple myeloma.
This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants with relapsed or refractory multiple myeloma.
This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM).
This is an open-label, dose-escalation study of the PIM kinase inhibitor INCB053914 in subjects with advanced malignancies.
This study is intended for men and women at least 18 years of age who have relapsed and/or refractory multiple myeloma. This 2-arm randomized pilot study will test the safety, tolerability and efficacy of NY-ESO-1C259T alone (Arm 1) or in combination with pembrolizumab (Arm 2) in subjects who have the appropriate HLA-A2 marker, and whose bone marrow expresses the NY-ESO-1 and/or LAGE-1a protein.
The purpose of this study is to learn more about ways to prevent or delay relapse of multiple myeloma (MM). This study will determine the best dosing schedule of LBH589 maintenance therapy as well as the safety (side effects) and tolerability of LBH589 maintenance therapy after autologous hematopoietic cell transplant (HCT).
Following consent, enrolled subjects will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of investigational drug product (bb21217). Following manufacture of the drug product, subjects will receive lymphodepletion prior to bb21217 infusion.
A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma.
Phase I: The primary purpose of this study phase is to determine the best dose also referred to as the maximum tolerated dose (MTD) of Selinexor when used in combination with high-dose melphalan as a conditioning regimen for hematopoietic cell transplant. Phase II: The primary purpose of this study phase is to assess the complete response (CR) conversion rate.
The purpose of this study is to test what effects (good and bad) a new cancer vaccine will have on participants and their cancer, when administered before and after their autologous hematopoietic cell transplant (HCT).
12902 USF Magnolia Drive
Tampa, FL 33612
Create your account today and get matched to myeloma treatment centers and specialists around the US.
Weekdays 9am - 5pm EST